- Assemblée générale 2024 de Roche
- Roche Generalversammlung 2024
- Roche Annual General Meeting 2024
- Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
- New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
- New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER)
- [Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19
- [Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
More ▼
Key statistics
On Monday, Roche Holding AG (RHHBY:QXI) closed at 32.18, 1.29% above its 52-week low of 31.77, set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.39 |
---|---|
High | 32.45 |
Low | 32.15 |
Bid | -- |
Offer | -- |
Previous close | 32.18 |
Average volume | 1.50m |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 15.98 |
Market cap | 211.66bn USD |
EPS (TTM) | 2.01 USD |
Annual div (ADY) | 1.39 USD |
---|---|
Annual div yield (ADY) | 3.92% |
Div ex-date | Mar 16 2023 |
Div pay-date | Mar 27 2023 |
Data delayed at least 15 minutes, as of Mar 18 2024 20:00 BST.
More ▼